for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fate Therapeutics Inc

FATE.O

Latest Trade

14.85USD

Change

0.14(+0.92%)

Volume

346,639

Today's Range

14.46

 - 

15.18

52 Week Range

11.00

 - 

22.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.71
Open
14.61
Volume
346,639
3M AVG Volume
16.54
Today's High
15.18
Today's Low
14.46
52 Week High
22.82
52 Week Low
11.00
Shares Out (MIL)
75.20
Market Cap (MIL)
1,106.19
Forward P/E
-10.36
Dividend (Yield %)
--

Latest Developments

More

Fate Therapeutics Prices Underwritten Public Offering Of 8.6 Mln Shares At $17.50/Shr

Fate Therapeutics Announces Proposed Public Offering Of Common Stock

Fate Therapeutics Inc Posts Loss Per Share Of $0.36

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fate Therapeutics Inc

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Industry

Biotechnology & Drugs

Contact Info

3535 General Atomics Ct Ste 200

+1.858.8751803

http://fatetherapeutics.com/

Executive Leadership

William H. Rastetter

Independent Chairman of the Board

John Scott Wolchko

President, Chief Executive Officer, Director

John D. Mendlein

Independent Vice Chairman of the Board

Sarah Cooley

Senior Vice President - Clinical Translation

Daniel D. Shoemaker

Chief Scientific Officer

Key Stats

1.43 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.050

2017

-1.020

2018

-1.190

2019(E)

-1.420
Price To Earnings (TTM)
--
Price To Sales (TTM)
135.96
Price To Book (MRQ)
7.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.70
LT Debt To Equity (MRQ)
7.43
Return on Investment (TTM)
-64.08
Return on Equity (TTM)
-53.74

Latest News

Latest News

BRIEF-Fate Therapeutics Qtrly Loss Per Share $0.27

* FATE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Fate Therapeutics Files For Mixed Shelf Of Up To $150 Million

* FATE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: (https://bit.ly/2KD5gGz) Further company coverage:

BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune

* FATE THERAPEUTICS ANNOUNCES ADDITIONAL CLINICAL DATA FROM PHASE 1 STAGE OF PROTECT CLINICAL TRIAL OF PROTMUNE™

BRIEF-Fate Therapeutics Q4 Loss Per Share $0.29​

* FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy

* Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy

BRIEF-Fate Therapeutics Q2 ‍net loss per common share $0.23​

* Fate Therapeutics reports second quarter 2017 financial results

BRIEF-Fate Therapeutics to amend and restate loan and security agreement

* Fate Therapeutics Inc - on July 14, 2017 co entered into first amendment to amended and restated loan and security agreement - SEC filing

BRIEF-Fate Therapeutics reports Q1 loss per share of $0.24

* Research and development expenses were $8.0 million for Q1 of 2017 compared to $6.6 million for comparable period in 2016 Source text for Eikon: Further company coverage:

BRIEF-Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100

* Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 in advanced solid tumors Source text for Eikon: Further company coverage:

BRIEF-Fate Therapeutics qtrly net loss per common share $ 0.21

* Fate Therapeutics reports fourth quarter 2016 financial results

BRIEF-Fate Therapeutics says investigational new drug application for its cancer drug gets FDA clearance

* Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 natural killer cell cancer immunotherapy

BRIEF-Fate Therapeutics files to say resale of up to 20.9 mln shares of common

* Fate Therapeutics - files to say resale of up to 20.9 million shares of common stock by the selling stockholders named Source text: (http://bit.ly/2j64uYl) Further company coverage:

BRIEF-Fate Therapeutics files for resale of up to 20.9 mln shares of co's common stock by selling stockholders - SEC filing

* Fate Therapeutics Inc - files for resale of up to 20.9 million shares of co's common stock by the selling stockholders - SEC filing Source text: (http://bit.ly/2jkJRHz) Further company coverage:

BRIEF-Fate Therapeutics reports private financing

* Says entered into a definitive securities purchase agreement with certain institutional and other accredited investors

BRIEF-Fate Therapeutics reports Q3 2016 financial results

* Fate Therapeutics reports third quarter 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up